Karo Bio AB Report issue

For profit Phase 2 Phase 3
Founded: Huddinge Sweden (1987)
Status: No NME R&D (1987)

Organization Overview

First Clinical Trial
2006
NCT00776321
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Karo Pharma AB

Active Ingredients

Drugs in Phase 3 Trials (1)

eprotirome (4 trials)

Drugs in Phase 2 Trials (1)

ezetimibe (zetia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyslipidemias (Phase 2)

Hypercholesterolemia (Phase 3)

Hyperlipoproteinemia Type II (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2